Real-world insights on biomarker testing patterns and implications for mNSCLC therapy selection

Key Points

• This research examines the prevalence and impact of biomarker testing in patients with metastatic non-small cell lung cancer (mNSCLC).
• Analyzed testing patterns for biomarker assessments in mNSCLC patients.
• Assessed disparities in access to comprehensive testing.
• Evaluated the implications of testing on therapy selection and patient outcomes.
• Majority of patients did not receive comprehensive biomarker testing.
• Identified significant disparities in testing access.
• Potential for improved therapy selection and patient outcomes with better testing adherence.